This trial is active, not recruiting.

Condition healthy
Sponsor Mclean Hospital
Start date March 2012
End date December 2015
Trial size 12 participants
Trial identifier NCT01825096, 2012p00622


The principal advantages of functional magnetic resonance imaging (fMRI) with blood-oxygenation- level-dependent (BOLD) contrast for studying brain function are: non-invasiveness, ubiquitous availability, relatively high spatiotemporal resolution, and the ability to map function over the entire brain. Thus, BOLD fMRI is the most widely applied technology to study healthy brain function and pathophysiology associated with disease. In studies of drug abuse and psychiatric illness though, normal assumptions mapping BOLD signals to neurometabolism may be violated. Generally, these effects are ignored, resulting in large study-to-study variability.

Quantitative fMRI (qfMRI) measures metabolism directly and is more suitable for studies of drug abuse and psychiatric illness. However, qfMRI is too complex for routine use. Cerebral metabolism during brain activation during visual stimulation measured with a new fMRI approach that is simple enough for clinical applications will be compared to CMRO2 activation measured using standard qfMRI.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case-only
Time perspective cross-sectional
No intervention. Participants are scanned at baseline.

Primary Outcomes

Changes in brain activity associated with visual stimulation
time frame: cross-sectional, start and up to 6 minutes

Eligibility Criteria

Male or female participants from 18 years up to 40 years old.

Inclusion Criteria: - Male or female - 18 to 40 years old - Physically healthy by self-report Exclusion Criteria: Diagnosis of current drug abuse/dependence, including nicotine, as assessed by DSM-IV criteria - Current diagnosis of Axis I disorder using DSM-IV criteria, or any Axis I disorder within past 5 years - Current daily use of antipsychotic, antidepressant, or other psychoactive prescription drug, as well as daily use of non-prescription drugs - Life threatening or unstable medical illness, or one that can create marked change in mental state - Heavy caffeine use (greater than 300 mg on a regular, daily basis) - History of seizure disorder - Subjects that report any history or current major medical illness (cardiovascular, pulmonary, psychiatric, or neurological disorders) - Subjects who have metal in their body, suffer from claustrophobia or women who are pregnant or currently breast-feeding cannot participate in this research study. - Additional MR exclusion criteria may include people with: - Cardiac pacemakers - Metal clips on blood vessels (also called stents) - Artificial heart valves - Artificial arms, hands, legs, etc. - Brain stimulator devices - Implanted drug pumps - Ear implants - Eye implants or known metal fragments in eyes - Exposure to shrapnel or metal filings (wounded in military combat, sheet metal workers, welders, and others) - Other metallic surgical hardware in vital areas - Certain tattoos with metallic ink (subjects are asked to inform research staff if they have a tattoo) - Metal Containing Intrauterine Devices (IUDs). - Certain transdermal (skin) patches such as Transderm Scop (scopolamine for motion sickness), or Ortho Evra (birth control). Enrollment:

Additional Information

Official title Multi-Modal fMRI/NIRS for Estimation of CMRO2 for Neuroimaging Studies of Drug Abuse and Psychiatric Illness Problems
Principal investigator Lisa D Nickerson, PhD
Description Healthy subjects will undergo a single imaging session. During the imaging session, fMRI and simultaneous near-infrared spectroscopy measurements will be made during visual stimulation (e.g., viewing a flashing checkerboard). This is a methods development study focused on comparing a new method for estimating CMRO2 associated with brain activation with the standard fMRI approach for estimating CMRO2.
Trial information was received from ClinicalTrials.gov and was last updated in April 2015.
Information provided to ClinicalTrials.gov by Mclean Hospital.